NextStep Robotics

NextStep Robotics works at the intersection of rehabilitation, medical devices, and robotics, with a focused application: gait therapy for foot drop, including impairment associated with stroke and other neurological conditions. Its AMBLE product is described as a wearable ankle exoskeleton that supplies variable, graded assistance during walking. The company also describes a clinic-oriented model: adaptive assistance is intended to support patient-specific therapy while the device is designed for practical use by clinic staff. The company’s categories identify robotics, biotechnology, rehabilitation, and AI; its overview describes a longer-term direction toward software that can use collected data to help tailor training protocols. Its differentiation can therefore be described only in product terms: an ankle-focused robotic device, adaptive assistance during gait, and a stated emphasis on clinic usability and foot-drop rehabilitation.

The financing history shows a gradual, early-stage trajectory rather than a large recent capital raise. NextStep Robotics recorded a $900,000 seed round on February 6, 2018, followed by a $600,000 seed round on May 14, 2019 and a $1 million grant on August 21, 2019. A $500,000 convertible note followed on August 4, 2020. After a multi-year gap in the listed rounds, the company recorded $400,000 on January 10, 2024 and a $200,000 seed round led by TEDCO on November 13, 2024. The six listed rounds total $3.6 million. The company is categorized in the 11–50 employee band, while two current positions are listed, including co-founder and CEO Brad Hennessie, whose role began in 2017. That employee-band/position-count difference makes current team size difficult to pin down. Overall, the record indicates sustained product development and periodic financing, but limited evidence to assess revenue growth or scaling.